Sevirumab
Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.[1][2]
References
- ↑ Borucki, MJ; Spritzler, J; Asmuth, DM; Gnann, J; Hirsch, MS; Nokta, M; Aweeka, F; Nadler, PI et al. (2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral Research 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
- ↑ ClinicalTrials.gov
Monoclonal antibodies for infectious disease and toxins |
|---|
| | Fungal ("-fung-") | |
|---|
| | Viral ("-vi(r)-") | |
|---|
| | Bacterial ("-ba(c)-") | Human ("-bacu-") | |
|---|
| Mouse ("-baco-") | |
|---|
| Chimeric ("-baxi-") | |
|---|
| Humanized ("-bazu-") | |
|---|
|
|---|
| | Toxin ("-tox(a)-") | Human ("-toxu-") | |
|---|
| Humanized ("-toxazu-") | |
|---|
|
|---|
| |
|
